|
|
|
| Meta-analysis of Bevacizumab combined with Cisplatin in the treatment of malignant pleural effusion of lung cancer |
| WANG Bo1 LIU Jiajia2 WAN Haiyu1 ZHANG Xiaoyan1 ZHENG Huixia3 |
1.The First Clinical Medical College, Shanxi Medical University, Shanxi Province, Taiyuan 030000, China;
2.Department of Oncology, Shanxi Hospital of Traditional Chinese Medicine, Shanxi Province, Taiyuan 030000, China;
3.Department of Pathology, the First Hospital of Shanxi Medical University, Shanxi Province, Taiyuan 030000, China |
|
|
|
Abstract Objective To evaluate the clinical efficacy of Bevacizumab combined with Cisplatin in the treatment of malignant pleural effusion of lung cancer. Methods The clinical data were collected from Chinese Journal full-text Database, Wanfang Data, VIP, Chinese Biomedical Literature Service system, PubMed, Embase, Central and Medline from the establishment of the database to August 2021. Two systematic reviewers searched the clinical randomized controlled trial of Bevacizumab combined with Cisplatin in the treatment of malignant pleural effusion of lung cancer, and then screened the literatures, extracted the data in the literature, and evaluated the quality of the literatures. The data were analyzed by Revman 5.3 software. Results A total of 17 studies were included, with a total of 1028 patients. The results of meta-analysis showed that the clinical efficacy (OR = 4.02, 95%CI:2.97 to 5.43, P ＜ 0.000 01) of experimental group was better than the control group, vascular endothelial growth permeability factor level in pleural effusion (MD = 53.24, 95%CI:-55.46 to -51.03, P ＜ 0.000 01) in the experimental group were significantly higher than those in the control group, the difference was statistically significant. The gastrointestinal adverse reactions in the control group (OR = 0.64, 95%CI: 0.43 to 0.96, P = 0.03) were significantly higher than those in the experimental group, the difference was statistically significant. There was no significant difference in serum carcinoembryonic antigen level, overall adverse reactions, bone marrow suppression and liver and kidney function injury between the two groups (P ＞ 0.05). Conclusion Bevacizumab combined with Cisplatin pleural perfusion is more effective in the treatment of malignant pleural effusion of lung cancer. As the evaluation of the clinical literature quality of this study is not high, it is necessary to carry out more meticulous, detailed, high-quality, and randomized double-blind and multicenter clinical controlled trials to more effectively demonstrate its clinical efficacy in the treatment of malignant pleural effusion of lung cancer.
|
|
|
|
|
|
[1] Masago K，Fujimoto D，Fujita S，et al. Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer [J]. Mol Clin Oncol，2015，3（2）：415-419.
[2] Clive AO，Kahan BC，Hooper CE，et al. Predicting survival in malignant pleural effusion：Development and validation of the LENT prognostic score [J]. Thorax，2014，69（12）：1098-1104.
[3] Popper HH. Progression and metastasis of lung cancer [J].Cancer Metastasis Rev，2016，35（1）：75-91.
[4] Nie K，Zhang Z，You Y，et al. A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer [J]. Thorac Cancer，2020，11（1）：8-14.
[5] Bradshaw M，Mansfield A，Peikert T. The role of vascular endothelial growth factor in the pathogenesis，diagnosis and treatment of malignant pleural effusion [J]. Curr Oncol Rep，2013，15（3）：207-216.
[6] 宋延海.贝伐单抗与顺铂联合治疗非小细胞肺癌恶性胸腔积液的疗效观察[J].中国医药指南，2020，18（31）：110-111.
[7] 吴田.贝伐单抗结合顺铂治疗NSCLC恶性胸腔积液患者的价值分析[J].国际医药卫生导报，2019（19）：3281-3284.
[8] 崔晓旭.贝伐珠单抗联合顺铂治疗肺癌恶性胸水的临床疗效[J].智慧健康，2019，5（17）：139-140.
[9] 张娜，何文娴，杨雪梅，等.贝伐单抗联合顺铂胸腔灌注治疗肺腺癌恶性胸腔积液[J].昆明医科大学学报，2019， 40（4）：117-120.
[10] 胡强.贝伐单抗联合顺铂胸腔灌注治疗肺腺癌恶性胸腔积液的疗效观察[J].中国医药指南，2019，17（5）： 132-133.
[11] 吴晓文，黄银梅，蔡东林.分析胸腔内注射治疗肺癌恶性胸腔积液患者的临床疗效[J].中国实用医药，2019， 14（3）：67-68.
[12] 昂冰，武乐，周彩云.贝伐珠单抗联合顺铂治疗肺癌恶性胸水的临床疗效[J].中国肿瘤生物治疗杂志，2018， 25（11）：1176-1179.
[13] 李凤玲.贝伐单抗联合顺铂对非小细胞肺癌恶性胸腔积液的治疗效果[J].世界最新医学信息文摘，2017，17（87）：99-100.
[14] 白萌.贝伐单抗和顺铂联合治疗非小细胞肺癌恶性胸腔积液的效果分析[J].河南医学研究，2017，26（4）：672-673.
[15] 薛丹凤，赵相军.贝伐单抗联合顺铂对非小细胞肺癌胸腔积液的治疗作用研究[J].中国医药导刊，2017，19（4）：377-378.
[16] 林凤华，苏伟平，金润女.贝伐单抗联合顺铂治疗非小细胞肺癌恶性胸腔积液临床研究[J].临床军医杂志，2016， 44（7）：698-700.
[17] 陈铁军，李琳琳，王月，等.贝伐单抗联合顺铂胸腔灌注治疗肺腺癌恶性胸腔积液的临床研究[J].数理医药学杂志，2016，29（2）：172-173.
[18] 陈雷，夏书月.贝伐单抗联合顺铂治疗非小细胞肺癌恶性胸腔积液的效果和安全性[J].上海交通大学学报（医学版），2015，35（8）：1194-1198.
[19] 曲博，姜威，周志明.贝伐单抗联合顺铂治疗非小细胞肺癌恶性胸腔积液的临床研究[J].中国医科大学学报，2015，44（7）：648-652.
[20] 杜楠，赵辉，王海滨，等.顺铂联合贝伐珠单抗对老年肺癌胸腔积液血管内皮生长因子表达的影响及疗效观察[J].中华临床医师杂志（电子版），2012，6（20）：6291-6295.
[21] 刘沙.顺铂联合安维汀腔内治疗恶性胸腹腔积液的临床分析[J].世界中医药，2016，3：973-974.
[22] 崔志勤，齐建考，汤肖，等.贝伐单抗联合顺铂对非小细胞肺癌恶性胸腔积液的治疗效果分析[J].东方药膳，2019（24）：100.
[23] Romaszko AM，Doboszynska A. Multiple primary lung cancer：a literature review [J]. Adv Clin Exp Med，2018， 27（5）：725-730.
[24] Schwartz AG，Cote ML. Epidemiology of lung cancer [J]. Adv Exp Med Biol，2016，893：21-41.
[25] Wang S，Zimmermann S，Parikh K，et al. Current diagnosis and man-agement of small-cell lung cancer [J]. Mayo Clin Proc，2019，94：1599-1622.
[26] Dartevelle PG，Mitilian D，Fadel E. Extend-ed surgery for T4 lung cancer：a 30 years ‘experience’ [J]. Gen Thorac Cardiovasc Surg，2017，65（6）：321-328.
[27] Shojaee S，Singh I，Solsky I，et al. Malignant pleural effusion at presentation in patients with small-cell lung cancer [J]. Respiration 2019，98（3）：198-202.
[28] Asciak R，Rahman NM. Malignant pleural effusion：from diagnostics to therapeutics [J]. Clin Chest Med，2018，39（1）：181-193.
[29] Skok K，Hladnik G，Grm A，et al. Malignant pleural effusion and its current management：a review [J]. Medicina（Kaunas），2019，55（8）：490.
[30] Stojanovska V，Prakash M，McQuade R，et al. Oxaliplatin treatment alters systemic immune responses [J]. Biomed Res Int，2019，2019：4650695.
[31] Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor [J]. Am J Physiol Cell Physiol，2001，280（6）：C1375-C1386.
[32] Chen Y，Mathy NW，Lu H. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer（Review） [J]. Mol Med Rep，2018，17（6）：8019-8030.
[33] Costanzo FD，Mazzoni F，Mela MM，et al. Bevacizumab in non-small cell lung cancer.[J]. Drugs，2008，68（6）：737-746.
[34] 黄彬.贝伐珠单抗和顺铂联合治疗非小细胞肺癌恶性胸腔积液的疗效评价[J].国际呼吸杂志，2016，36（11）：814-817. |
|
|
|
